Rani Therapeutics Announces Topline Results From Phase 1 Study Of Oral Anti-Interleukin 12/23 Antibody
Portfolio Pulse from Benzinga Newsdesk
Rani Therapeutics announced positive Phase 1 study results for RT-111, an oral anti-Interleukin 12/23 antibody, showing high bioavailability and tolerability with no serious adverse events. Celltrion has the right of first negotiation for worldwide rights to RT-111 post-trial. This marks Rani's third successful Phase 1 trial using RaniPill technology. A conference call is scheduled for today.
February 05, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rani Therapeutics' successful Phase 1 trial results for RT-111 could positively impact investor sentiment, given the high bioavailability, tolerability, and no serious adverse events reported.
The positive outcome of the Phase 1 trial for RT-111, especially in terms of bioavailability and safety, is likely to be viewed favorably by investors. The successful completion of three Phase 1 trials using RaniPill technology further solidifies Rani Therapeutics' position in the market. The partnership potential with Celltrion for worldwide rights could also be a significant catalyst for the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100